HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device 'Alpha DaRT (Diffusing Alpha Radiation Therapy),' developed by Alpha Tau Medical Ltd.

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program -- First-in-kind technology ...
KXAN

Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer

– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – This clinical trial is designed based on the results of an ...
iaea.org

New Technique to Fight Prostate Cancer: IAEA organizes first-of-a-kind training for Radiopharmacists

For the first time, radiopharmacists from across Central and Eastern Europe learned about an emerging technique in treating prostate cancer at an IAEA course organized at the National Centre for ...